OdishaPlus Bureau
Pharma major Lupin Ltd on Wednesday announced the launch of Favipiravir in India under the brand name Covihalt. The medicine will aid for the treatment of mild to moderate COVID-19. It is available as 200 mg tablets in the form of a strip of 10 tablets and priced at Rs 49 per tablet.
Earlier, Favipiravir had received authorisation from the Drug Controller General of India (DCGI) for emergency use. Lupin’s Covihalt dosage strength has been developed keeping in mind the convenience of administration.
Rajeev Sibal, President of India region formulations at Lupin Ltd said, “COVID-19 is a global pandemic and in India we are seeing a surge in the number of cases on a daily basis. In these tough times, it is our duty to support the nation in fighting this pandemic and ensuring affordable drugs are made available for impacted patients.”
Lupin has 15 manufacturing sites, 7 research centres and more than 20,000 professionals working globally. The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and active pharma ingredients in over 100 markets in the United States, India, South Africa and across the Asia Pacific, Latin America, Europe and Middle East regions. Shares of Lupin were trading 0.32 per cent higher at Rs 943.70 apiece on BSE
On August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name ””FluGuard”” for the treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India.
